A5210: PHASE IB/IIA DOSE-FINDING SAFETY AND ACTIVITY STUDY OF AMD11070

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objectives of this study are to determine the safety of several dose levels of AMD11070 (with the starting dose determined by the results of A5191 administered over 10 days with HIV-infected subjects who harbor X4-tropic virus and to determine the proportion of subjects per cohort who have a ?1 log10 rlu reduction in X4-tropic virus during 10 days of AMD11070 treatment or in the 7 days following treatment discontinuation, and to describe changes from baseline to day 10 in log10 rlu corresponding to X4-tropic virus